TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/26/2026
Back to search
Official data from USPTO
HEALTH. ILLUMINATED.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HEALTH. ILLUMINATED.
ST13
US500000090602703Class
5, 10, 42, 44
Filing
90602703
Registration
6981371
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
52
Latest update
05/29/2026
Trademark type
Word
Nice classes
5, 10, 42, 44
Filing date
03/25/2021
Registration date
02/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/14/2023
Last transaction
05/29/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2022-02-00
First use in commerce
2022-02-00
Drawing code
4
Owner type
03
Owner location
Salt Lake City, UT, US
Examiner
DE JONGE, KATHLEEN
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Myriad Genetics, Inc.
Representatives
Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical test kits comprising chemical reagents and chemical preparations for medical use in connection with the detection of gene mutationsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; medical diagnostic reagentsassayschemical preparationsdiagnostic test kits consisting primarily of reagents for medical diagnostic purposestesting of fluids; chemical reagents for medical use in connection with the detection of gene mutationsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic test kits comprised of chemical reagents and chemical preparations for medical use in connection with the detection of gene mutationsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic kits consisting primarily of reagents for body fluid analysis and nucleic acid analysis and for detecting genetic conditionsdisordersdiseases for medical use
Class 10
Medical test kits comprising specimen collection tubes and containers for collecting patient specimensprinted test formsprinted mailing materialsprinted user information inserts used in connection with the detection of gene mutationsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; sample preparation device for medical diagnostic uses; medical apparatus and instruments for diagnostic useapparatus for medical diagnostic testing in the fields of tissue-based diagnostic testingcytology and cell-based testing; bloodurinesaliva medical specimen collection kits consisting of test tubes and self-mailerused for health and genetic analysis and diagnostics
Class 42
Clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human geneticsfor scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery servicespharmaceutical research servicespre-clinical medical research screeningclinical trialresearch and evaluation services; biosignaturesgenomicsproteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discoverydrug screening for scientific research purposespre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis servicesevaluation of non-genetic biological response to diseasedrugsthe environment; providing temporary use of non-downloadable computer software for customizingselectingordering health and genetic analysis and diagnostic kits and assays and for accessingviewingstoring health and genetic information via electronicopticalwireless communication networks; scientific research analysis and consulting services which use bioinformatics; gene and tissue bank services that provide DNA samples for use in future medical and scientific researchmedical and scientific educational studies and development of new medical and scientific products and validation thereof
Class 44
Genetic testing services for diagnostic or treatment purposes; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of geneticsthe identification of genes that predispose individuals to common diseases and health disorders for diagnostic or treatment purposes; medical testingproviding reference and clinical laboratory tests that detectclassifyanalyzeevaluate gene mutationsgene variantsgene expression profilesother molecular abnormalitiesindicatorsmarkers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimensprognosing diseasepredicting disease progression or disease severityidentifying predisposition to developing diseaseevaluating the efficacy or toxicity of medical treatmentsidentifying risk factors of diseasemolecular profiles associated with successful therapies or treatment regimensfor classifying disease progression or severity; medical diagnostic testingmonitoringreporting services; internet-based health care information services; providing an internet website for medical professionals featuring medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical informationproviding medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatmentdrugdosage levels for patients through the use of data obtained through personalized pharmacogenetic testingproteomics and other biological testingindividual behaviors including medication complianceexercise dietsleep patterns and languageepigenetic and environmental factorsbioinformatics analysis and medical and pharmaceutical consultation services related theretodiscussion and interpretation with clients of medical test results and medical analysis related thereto; medical testing servicesproviding medical tests that measureanalyzeinterpret genes and medications of patientsenvironmentalother factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorptiondistributionmetabolismexcretion and each medication's receptor activitymechanism of actionpathways of response and then measures the impact of genomic changes across these pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patientspersonalize medication selectiontreatment options and choices for patientsidentify potentially harmful drug interactionscalculate drug dosage adjustments for patients; and medical information servicespreparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objectiveevidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications
Publications
History of USPTO decisions and trademark events.
52 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/26/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/26/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/26/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/26/2026
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/02/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/09/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/09/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/09/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/09/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/09/2024
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/26/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/14/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/14/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/07/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/06/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/06/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/05/2023
EX2G
SOU EXTENSION 2 GRANTED
01/05/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/04/2023
IUAF
USE AMENDMENT FILED
12/14/2022
EXT2
SOU EXTENSION 2 FILED
12/14/2022
EEXT
SOU TEAS EXTENSION RECEIVED
12/14/2022
EISU
TEAS STATEMENT OF USE RECEIVED
12/14/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/27/2022
EX1G
SOU EXTENSION 1 GRANTED
07/25/2022
EXT1
SOU EXTENSION 1 FILED
07/25/2022
EEXT
SOU TEAS EXTENSION RECEIVED
07/25/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/17/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/17/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/17/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/27/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
01/27/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/27/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/27/2022
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/25/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/30/2021
PUBO
PUBLISHED FOR OPPOSITION
11/30/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/25/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
10/25/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/25/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
10/25/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/25/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/08/2021
GNRT
NON-FINAL ACTION E-MAILED
09/08/2021
CNRT
NON-FINAL ACTION WRITTEN
09/08/2021
DOCK
ASSIGNED TO EXAMINER
09/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/30/2021
NWAP
NEW APPLICATION ENTERED
03/29/2021
Continuous trademark protection
Get notified about every new filing that threatens HEALTH. ILLUMINATED. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.